HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Surface Antigens (Surface Antigen)

Subscribe to New Research on Surface Antigens

Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.

Also Known As:

Surface Antigen; Surface Antigens, Cell; Antigens, Surface; Cell Surface Antigen; Immunologic Surface Markers; Markers, Immunological Surface; Surface Markers, Immunologic; Antigen, Cell Surface; Antigen, Surface; Antigens, Cell Surface; Immunological Surface Markers; Markers, Immunologic Surface; Surface Antigen, Cell; Cell Surface Antigens; Surface Markers, Immunological

Networked: 4354 relevant articles (101 outcomes, 337 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Biological Factors: 1315
- Antigens: 114404
  - Surface Antigens: 4354

Experts

1.	Hviid, Lars: 24 articles (01/2014 - 04/2002)
2.	Staalsoe, Trine: 19 articles (08/2010 - 04/2002)
3.	Theander, Thor G: 17 articles (02/2013 - 04/2002)
4.	Rogerson, Stephen J: 13 articles (09/2012 - 04/2002)
5.	Marsh, Kevin: 12 articles (01/2016 - 02/2002)
6.	Raimondo, Giovanni: 12 articles (10/2015 - 03/2006)
7.	Menne, Stephan: 12 articles (09/2015 - 01/2002)
8.	Pollicino, Teresa: 10 articles (10/2015 - 03/2006)
9.	Deloron, Philippe: 10 articles (01/2015 - 07/2004)
10.	Su, Ih-Jen: 10 articles (09/2014 - 12/2003)

Related Diseases

1.	Infection 08/01/2012 - "Our results demonstrated that V. anguillarum MVAV6203 (pUTatLNG40), which harbours a low-copy plasmid-loaded antigen surface display system under the control of a constitutive promoter, presented the best protective efficacy against the infection of Vibrio anguillarum (relative per cent survival, RPS = 85%) and Edwardsiella tarda (RPS = 70%)." 12/01/1975 - "The results indicate that the surface-antigen-adsorbed vaccine induced high titres of serum antibody, and gave significant protection against challenge infection." 04/01/2006 - "Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of toxoplasma gondii induces immune response and protection against infection in mice." 03/30/1991 - "Two regimens by which vaccine was injected intradermally into children between 0 and 4 years old led to peak geometric mean (95% CI) concentrations of antibody against HBV surface antigen of 270 (202-358) and 555 (418-748) mlU/ml. The third regimen--intramuscular vaccination of children aged between 0 and 4 years--gave geometric mean peak antibody concentrations of 926 (765-1122) mlU/ml. A fourth regimen was intramuscular vaccination of children between 1 and 9 months old, which gave geometric mean antibody concentrations of 5431 (3903-75,456) mlU/ml. Despite these widely divergent responses and a 89% decay in antibody over the first 2 years, vaccination against HBV was 97% effective in preventing chronic infection. " 08/01/2008 - "Maybe the HBV strains in this study represent a natural end-stage of seemingly cleared HBV infection, in which HBV maintains a low level of possibly non-infectious replication, after sacrificing its immunologically offending surface antigen, thus avoiding final clearance by the immune system."
2.	Neoplasms (Cancer) 03/01/2005 - "Challenges that remain to be addressed if the full potential of primary cultures as a model system is to be realized include isolation, culture and characterization of stem cells, improved methodology to induce or maintain a fully differentiated, androgen-responsive phenotype, and identification of cell surface antigens or other markers with which to purify pure populations of live cancer or premalignant cells apart from non-malignant epithelial cells prior to culture." 01/01/2015 - "The anti-cancer efficacy of antibody-drug conjugates is thought to rely on their uptake by cancer cells expressing the surface antigen. " 10/20/2003 - "Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner." 06/01/2003 - "Radiolabelled MAbs against cell surface antigens have improved in vivo tumor diagnosis and treatment. " 08/15/2001 - "Using a series of human tumor cells (SNB19, SNB79, 143N2, and SHEP), we observed a distinct efficacy of human anti-FasR antibody with an apparent correlation with Fas cell surface antigen expression. "
3.	Hepatitis B 03/01/2014 - "The aim of this study was to verify antibody levels of antibody against hepatitis B virus surface antigen (anti-HBs) in children aged 1 to 15 years who received vaccination against hepatitis B in the central province of Iran, Semnan. " 08/01/2006 - "The study describes expression and purification of recombinant hepatitis B small surface antigen (rHBsAg hereafter) in methylotrophic yeast Pichia pastoris strain GS115. " 10/01/1990 - "The results of these studies were correlated with the histopathology and immunohistochemical stains for hepatitis B core and surface antigens. " 08/01/2015 - "Serum hepatitis B virus surface antigen was present in 1,083 (68.5%) patients, and hepatitis B was found to be the only etiological factor in 938 (59.3%) of all patients. " 03/01/2015 - "To evaluate proportion and predictors of poor response in infants and appraise booster seroprotection, we surveyed 2047 infants in Shanghai and detected antibody to hepatitis B (HB) surface antigen (anti-HBs). "
4.	Malaria 08/01/2015 - "Since the discovery of circumsporozoite protein (CSP), a major sporozoite surface antigen, by Ruth Nussenzweig and Victor Nussenzweig in the early 1980s, the role of CSP in protection against malaria has been extensively investigated. " 08/01/1999 - "For 9 years we have monitored individuals living in an area of low-intensity, seasonal, and unstable malaria transmission in eastern Sudan, and we have used this database to study the acquisition, specificity, and duration of the antibody response to variant parasitized erythrocyte surface antigens. " 04/01/1997 - "In the first phase III efficacy trial of the malaria vaccine SPf66 in Africa, MOIs in SPf66- and placebo-vaccinated children were analyzed by polymerase chain reaction-restriction fragment length polymorphism of the Plasmodium falciparum merozoite surface antigen 2 (MSA2). " 02/01/1995 - "Two hundred fourteen adult individuals were selected for studies to assess their immune responses against the malaria vaccine candidate ring-infected erythrocyte surface antigen (RESA). " 07/01/1991 - "Genetic studies on a major merozoite surface antigen of the malaria parasite of rodents, Plasmodium chabaudi."
5.	Hepatitis 05/01/2003 - "For hepatitis surface antigen expression in eukaryotic cells, the vector pRc/CMV is superior to pSG5UTPL/Flag, and pRc/CMV-S and pRc/CMV-MS are the most efficient in the pRc/CMV clones. " 12/01/2012 - "A total of 530 children enrolled into the study, and 352 (66.4 %) of them had protective antibody to hepatitis surface antigens (anti-HBs) titer greater than 10 mIU/ml. The proportions of children with low, intermediate, and high anti-HB titers are different for those under 3 years of age. " 03/12/2007 - "Analysis comprised HIV-positive patients in the ICoNA study without acute hepatitis who had >or= 1 positive HCV antibody test and > 1 positive HBV surface antigen test. " 09/01/1996 - "During the study period of 28 days, protective antibody titers to hepatitis surface antigen (anti-HBs10 mIU ml-1) were observed in 11 of 81 subjects receiving rhGM-CSF, but in none of the controls (P = 0.035). " 10/14/2015 - "The endemicity of hepatitis surface antigen in Indonesia is intermediate to high with a geographical difference. "

Related Drugs and Biologics

1.	Hepatitis B Surface Antigens (HBsAg)
2.	Antigens
3.	Antibodies
4.	DNA (Deoxyribonucleic Acid)
5.	Monoclonal Antibodies
6.	Hepatitis B e Antigens
7.	Immunoglobulin G (IgG)
8.	Surface Antigens (Surface Antigen)
9.	rituximab (Mabthera)
10.	Interferon-alpha (Interferon Alfa)

Related Therapies and Procedures

1.	Immunotherapy
2.	Drug Therapy (Chemotherapy)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Therapeutics
5.	Highly Active Antiretroviral Therapy (HAART)